image
Healthcare - Biotechnology - NASDAQ - US
$ 41.22
-7.13 %
$ 2.04 B
Market Cap
-22.16
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MIRM stock under the worst case scenario is HIDDEN Compared to the current market price of 41.2 USD, Mirum Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MIRM stock under the base case scenario is HIDDEN Compared to the current market price of 41.2 USD, Mirum Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MIRM stock under the best case scenario is HIDDEN Compared to the current market price of 41.2 USD, Mirum Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
337 M REVENUE
80.76%
-87.6 M OPERATING INCOME
19.74%
-87.9 M NET INCOME
46.18%
10.3 M OPERATING CASH FLOW
114.55%
-90.1 M INVESTING CASH FLOW
15.93%
17.7 M FINANCING CASH FLOW
-94.74%
99.4 M REVENUE
10.00%
-24.2 M OPERATING INCOME
-90.96%
-23.8 M NET INCOME
-67.12%
-5.07 M OPERATING CASH FLOW
-127.21%
641 K INVESTING CASH FLOW
103.55%
5.34 M FINANCING CASH FLOW
38.23%
Balance Sheet Mirum Pharmaceuticals, Inc.
image
Current Assets 393 M
Cash & Short-Term Investments 280 M
Receivables 78.3 M
Other Current Assets 34.2 M
Non-Current Assets 278 M
Long-Term Investments 12.5 M
PP&E 9.81 M
Other Non-Current Assets 256 M
41.79 %11.67 %5.10 %38.11 %
Current Liabilities 127 M
Accounts Payable 14.6 M
Short-Term Debt 0
Other Current Liabilities 112 M
Non-Current Liabilities 319 M
Long-Term Debt 308 M
Other Non-Current Liabilities 10.5 M
3.28 %25.15 %69.21 %
EFFICIENCY
Earnings Waterfall Mirum Pharmaceuticals, Inc.
image
Revenue 337 M
Cost Of Revenue 81.6 M
Gross Profit 255 M
Operating Expenses 343 M
Operating Income -87.6 M
Other Expenses 336 K
Net Income -87.9 M
RATIOS
75.77% GROSS MARGIN
75.77%
-26.00% OPERATING MARGIN
-26.00%
-26.10% NET MARGIN
-26.10%
-38.97% ROE
-38.97%
-13.11% ROA
-13.11%
-16.29% ROIC
-16.29%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mirum Pharmaceuticals, Inc.
image
Net Income -87.9 M
Depreciation & Amortization 23.6 M
Capital Expenditures -993 K
Stock-Based Compensation 48.4 M
Change in Working Capital 22.6 M
Others 474 K
Free Cash Flow 9.33 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mirum Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for MIRM of $54.7 , with forecasts ranging from a low of $39 to a high of $70 .
MIRM Lowest Price Target Wall Street Target
39 USD -5.39%
MIRM Average Price Target Wall Street Target
54.7 USD 32.74%
MIRM Highest Price Target Wall Street Target
70 USD 69.82%
Price
Max Price Target
Min Price Target
Average Price Target
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Mirum Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
6.77 M USD 3
3-6 MONTHS
1.9 M USD 4
6-9 MONTHS
118 K USD 1
9-12 MONTHS
1.18 M USD 3
Bought
280 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
13.9 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update. businesswire.com - 1 week ago
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities Mirum Pharmaceuticals boasts a strong portfolio with LIVMARLI, Ctexli, and Cholbam, as well as two promising pipeline candidates --volixibat and MRM-3379-- both of which carry billion-dollar potential. The company is expected to be cash flow positive by the end of FY 2025, with significant revenue growth projected for 2025 and 2026. Upcoming data presentations and earnings could drive the stock higher, with analysts' price targets ranging from $54 to $74 per share. seekingalpha.com - 2 weeks ago
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025. businesswire.com - 2 weeks ago
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses. businesswire.com - 3 weeks ago
Mirum's LIVMARLI Now FDA Approved in Tablet Formulation FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #alagillesyndrome--Mirum's LIVMARLI Now FDA Approved in Tablet Formulation. businesswire.com - 1 month ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). businesswire.com - 1 month ago
LIVMARLI Now Approved in Japan for ALGS and PFIC FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC. businesswire.com - 1 month ago
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven by LIVMARLI and the newly acquired bile acid medicines. seekingalpha.com - 1 month ago
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock. zacks.com - 1 month ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). businesswire.com - 2 months ago
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same. zacks.com - 2 months ago
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Chris Peetz - Chief Executive Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Jessica Fye - JPMorgan David Lebowitz - Citi Rohit Bhasin - Morgan Stanley Ryan Deschner - Raymond James Jonathan Wolleben - Citizens JMP Operator Hello, and welcome to Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update. My name is Elliot, and I'll be your coordinator today. seekingalpha.com - 2 months ago
8. Profile Summary

Mirum Pharmaceuticals, Inc. MIRM

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.04 B
Dividend Yield 0.00%
Description Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Contact 950 Tower Lane, Foster City, CA, 94404 https://www.mirumpharma.com
IPO Date July 18, 2019
Employees 322
Officers Mr. Christopher Peetz Chief Executive Officer & Director Mr. Andrew McKibben Senior Vice President, Strategic Finance & Investor Relations Mr. Eric H. Bjerkholt M.B.A. Chief Financial Officer Dr. Joanne M. J. Quan M.D. Chief Medical Officer Ms. Erin Campany Chief People Officer Dr. Jean-Luc Girardet Ph.D. Chief Technical Officer Mr. Peter Radovich M.B.A., Ph.D. Chief Operating Officer & President Dr. Pamela Vig Ph.D. Chief Scientific Officer Mr. Paul K. Ross Chief Compliance Officer Ms. Lara Longpre MBA, MSC Chief Development Officer